The royaly rate is not disclosed, but here is what the company website says:
EpiCept is a licensor to Myriad Genetics, Inc. for the exclusive worldwide right to develop and commercialize the MX90745 series of apoptosis inducers. Under the terms of the agreement, Myriad is responsible for all clinical development and commercialization of compounds from this series. Myriad has initiated clinical trials for Azixa™* (MPC-6827), for the treatment of brain cancer and other solid tumors. The agreement requires that Myriad make licensing, research and milestone payments to EpiCept, assuming the successful commercialization of a compound for the treatment of cancer, as well as pay a royalty on product sales. The Company is eligible to receive up to $27 million in milestone payments from Myriad for the development of Azixa.